publication . Article . Other literature type . 2009

DONEPEZIL TREATMENT OF PATIENTS WITH MCI: A 48-WEEK RANDOMIZED, PLACEBO- CONTROLLED TRIAL

Steven Ferris;
Restricted
  • Published: 28 Jan 2009 Journal: Neurology, volume 72, pages 1,555-1,561 (issn: 0028-3878, eissn: 1526-632X, Copyright policy)
  • Publisher: Ovid Technologies (Wolters Kluwer Health)
Abstract
Background: Treatment of mild cognitive impairment (MCI) with cholinesterase inhibitors may improve symptoms. Methods: In this multicenter, randomized, placebo-controlled trial, subjects with MCI entered a 3-week placebo run-in period followed by 48 weeks of double-blind donepezil (5 mg/day for 6 weeks, then 10 mg/day for 42 weeks) or placebo treatment. Primary efficacy variables included change from baseline in the modified Alzheimer Disease Assessment Scale–cognitive subscale (ADAS-Cog) and Clinical Dementia Rating Scale–sum of boxes (CDR-SB) after 48 weeks of treatment (modified intention-to-treat analysis). Secondary efficacy measures evaluated cognition, be...
Subjects
Medical Subject Headings: mental disorders
free text keywords: Clinical Neurology
Powered by OpenAIRE Research Graph
Any information missing or wrong?Report an Issue